Analytical Data
-
基因名
MTA2
- Application
-
别名
MTA1L1; PID; Metastasis-associated 1-like 1; p53 target protein in deacetylase complex; Metastasis-associated protein MTA2
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O94776
-
表达区间
Met1~Cys394
-
分子量
49kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTA2, or Metastasis-associated protein 2, is a crucial component of the nucleosome remodeling and deacetylase (NuRD) complex, which plays significant roles in transcriptional regulation, cell differentiation, and various cellular processes. Research has increasingly focused on MTA2 due to its association with cancer metastasis and progression, as well as its potential as a therapeutic target. Elevated MTA2 levels have been observed in several types of cancers, including breast and ovarian cancers, where it correlates with poor prognosis. MTA2 participates in epigenetic regulation by influencing chromatin structure, leading to silencing or activation of specific genes involved in cellular growth and invasion. Furthermore, studies have suggested that MTA2 interacts with various signaling pathways, thus contributing to the oncogenic properties of tumor cells. Understanding the molecular mechanisms underlying MTA2 function and its involvement in tumorigenesis is critical for developing targeted therapies aimed at inhibiting its activity, which may offer new strategies for cancer treatment. Therefore, the characterization of MTA2 as a recombinant protein has become an essential focus, enabling researchers to investigate its structural properties and interactions with other proteins, ultimately paving the way for novel intervention strategies in cancer therapy.
